Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05108077CT.gov Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells | — | Unknown | — | — | — |
NCT03987698CT.gov Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma | — | Unknown | — | — | — |
NCT03047525CT.gov Study of DC-CTL Combined With CIK for Advanced Solid Tumor | — | Unknown | — | — | — |
NCT02886897CT.gov A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | — | Unknown | — | — | — |
NCT01924156CT.gov DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma | — | Unknown | — | — | — |
NCT00862303CT.gov DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating Patients With Renal Cell Carcinoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Renal Cell Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cik Cells (this asset) | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | P2 | CCC · 52 |
| Sorafenib | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P4 | BBB |
| Pazopanib | Imbioray (Hangzhou) Biomedicine Co., Ltd. | P4 | BBB |
| Belzutifan | Vall d'Hebron Institute of Oncology | P3 | BBB |
| Cyclosporin A | National Cancer Institute (NCI) | P2 | BB |
| Interferon-Alfa-2A | Central European Society for Anticancer Drug Research | P3 | BB |
| Everolimus | Merck Sharp & Dohme LLC | P4 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P3 | BB |
| Nivolumab | Fred Hutchinson Cancer Center | P4 | BB |
+42 more in the Renal Cell Carcinoma cohort
Other indications for Cik Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P3 | BB · 64 |
| Colorectal Cancer | — | P4 | B · 62 |
| Neoplasm | — | P2 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cik Cells in Renal Cell Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cik-cells-renal-cell-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →